FI
IOVA icon

Fosun International’s Iovance Biotherapeutics IOVA Stock Holding History

Fosun International’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-413,154
Closed -$9.33M – 262
2019
Q2 		$9.33M Hold
413,154
– – 0.62% 25
2019
Q1 		$3.92M Buy
413,154
+129,000
+45% +$1.25M 0.25% 59
2018
Q4 		$2.52M Buy
+284,154
New +$2.74M 0.15% 73

Other funds holding IOVA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fosun International's IOVA Position: Q3 2019 in Review

Fosun International sold out of Iovance Biotherapeutics (IOVA) in Q3 2019, closing a stake of 413,154 shares — an estimated $9.33M sold.

Fosun International first reported a position in IOVA in Q4 2018 and held it in 3 quarters. The position peaked at $9.33M in Q2 2019. 173 funds tracked by Wall St. Rank hold IOVA as of Q3 2019.

  • Fosun International reported no remaining Iovance Biotherapeutics position as of Q3 2019 after selling out during the quarter.
  • Fosun International sold 413,154 Iovance Biotherapeutics shares in Q3 2019, an estimated $9.33M.
  • Fosun International first reported a position in Iovance Biotherapeutics in Q4 2018 and held it in 3 quarters.
  • Fosun International's Iovance Biotherapeutics position peaked at $9.33M in Q2 2019.
  • 173 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2019.

Based on Fosun International's 13F filing for Q3 2019, filed 12 Nov 2019.